Beam Therapeutics (BEAM) shares rose about 8% in recent trading Wednesday. Leerink Partners upgraded the company's stock to outperform from market perform and adjusted price target upwards to $39 from $27.
Trading volume stood at 1.25 million shares, against a daily average of 845,000.
Price: 25.81, Change: +1.88, Percent Change: +7.86
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。